Efficacy of GnRH agonists in prostate cancer treatment is likely due to their specificity toward GnRH receptors found in the pituitary gland; however increasing evidence has indicated that the presence of GnRH receptors in tumors of the prostate, as demonstrated by the in vitro and in vivo studies mentioned previously, and of other organs, such as breast, uterus and ovary might be their additional molecular targets [40–42]. Here, GNRHR is linked to prostate cancer.